Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer

Enrico Cortesi, Luca Moscetti, Fabrizio Nelli, Filippo De Marinis, Ugo De Paula, Caterina Bangrazi, Maria Rita Migliorino, Vittorio Donato

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims and background: The purpose of this pilot study was to determine the safety and feasibility of a complete integrated approach, including induction chemotherapy with carboplatin/paclitaxel followed by accelerated hyperfractionated radiotherapy with concurrent chemotherapy, and then by consolidation chemotherapy for locally advanced stage III non-small cell lung carcinoma. Methods: Systemic doses of carboplatin AUC 6 and paclitaxel (200 mg/m2), 3 weeks out of 4, were planned as induction and consolidation chemotherapy. Weekly carboplatin AUC of 2 plus paclitaxel (50 mg/m2) were given during thoracic radiotherapy. Results: Eighteen patients were enrolled: 10 were evaluated at the end of chemoradiation and 8 received consolidation chemotherapy. On an intent-to-treat basis, 55% of patients achieved a response after induction therapy, whereas chemoradiation and consolidation therapy increased the response rate by 33% and 16%, respectively. No patient experienced grade >3 acute hematologic toxicity during systemic-dose chemotherapy. With the exception of one episode of a severe cardiac adverse event, non-hematologic toxicity was similarly tolerable. Severe acute adverse events observed during concurrent chemoradiation were mainly represented by esophagitis, resulting in interruption of the radiotherapy in 25% of patients. More notably, only one patient experienced serious non-hematologic late toxicity. Conclusions: Although the present approach seemed feasible, our data did not support any possible advantage in favor of this three-phase integrated treatment, and therefore the design will not be investigated in a subsequent phase II study.

Original languageEnglish
Pages (from-to)133-137
Number of pages5
JournalTumori
Volume93
Issue number2
Publication statusPublished - Mar 2007

Fingerprint

Consolidation Chemotherapy
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Radiotherapy
Induction Chemotherapy
Area Under Curve
Therapeutics
Drug Therapy
Esophagitis
Thorax
Safety

Keywords

  • Carboplatin
  • Concurrent chemoradiotherapy
  • Consolidation chemotherapy
  • Hyperfractionated radiotherapy
  • Induction chemotherapy
  • Non-small-cell lung cancer
  • Paclitaxel
  • Stage III

ASJC Scopus subject areas

  • Cancer Research

Cite this

Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer. / Cortesi, Enrico; Moscetti, Luca; Nelli, Fabrizio; De Marinis, Filippo; De Paula, Ugo; Bangrazi, Caterina; Migliorino, Maria Rita; Donato, Vittorio.

In: Tumori, Vol. 93, No. 2, 03.2007, p. 133-137.

Research output: Contribution to journalArticle

Cortesi, Enrico ; Moscetti, Luca ; Nelli, Fabrizio ; De Marinis, Filippo ; De Paula, Ugo ; Bangrazi, Caterina ; Migliorino, Maria Rita ; Donato, Vittorio. / Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer. In: Tumori. 2007 ; Vol. 93, No. 2. pp. 133-137.
@article{e5c0cc6f01874113853e5cc35baa5b45,
title = "Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer",
abstract = "Aims and background: The purpose of this pilot study was to determine the safety and feasibility of a complete integrated approach, including induction chemotherapy with carboplatin/paclitaxel followed by accelerated hyperfractionated radiotherapy with concurrent chemotherapy, and then by consolidation chemotherapy for locally advanced stage III non-small cell lung carcinoma. Methods: Systemic doses of carboplatin AUC 6 and paclitaxel (200 mg/m2), 3 weeks out of 4, were planned as induction and consolidation chemotherapy. Weekly carboplatin AUC of 2 plus paclitaxel (50 mg/m2) were given during thoracic radiotherapy. Results: Eighteen patients were enrolled: 10 were evaluated at the end of chemoradiation and 8 received consolidation chemotherapy. On an intent-to-treat basis, 55{\%} of patients achieved a response after induction therapy, whereas chemoradiation and consolidation therapy increased the response rate by 33{\%} and 16{\%}, respectively. No patient experienced grade >3 acute hematologic toxicity during systemic-dose chemotherapy. With the exception of one episode of a severe cardiac adverse event, non-hematologic toxicity was similarly tolerable. Severe acute adverse events observed during concurrent chemoradiation were mainly represented by esophagitis, resulting in interruption of the radiotherapy in 25{\%} of patients. More notably, only one patient experienced serious non-hematologic late toxicity. Conclusions: Although the present approach seemed feasible, our data did not support any possible advantage in favor of this three-phase integrated treatment, and therefore the design will not be investigated in a subsequent phase II study.",
keywords = "Carboplatin, Concurrent chemoradiotherapy, Consolidation chemotherapy, Hyperfractionated radiotherapy, Induction chemotherapy, Non-small-cell lung cancer, Paclitaxel, Stage III",
author = "Enrico Cortesi and Luca Moscetti and Fabrizio Nelli and {De Marinis}, Filippo and {De Paula}, Ugo and Caterina Bangrazi and Migliorino, {Maria Rita} and Vittorio Donato",
year = "2007",
month = "3",
language = "English",
volume = "93",
pages = "133--137",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer

AU - Cortesi, Enrico

AU - Moscetti, Luca

AU - Nelli, Fabrizio

AU - De Marinis, Filippo

AU - De Paula, Ugo

AU - Bangrazi, Caterina

AU - Migliorino, Maria Rita

AU - Donato, Vittorio

PY - 2007/3

Y1 - 2007/3

N2 - Aims and background: The purpose of this pilot study was to determine the safety and feasibility of a complete integrated approach, including induction chemotherapy with carboplatin/paclitaxel followed by accelerated hyperfractionated radiotherapy with concurrent chemotherapy, and then by consolidation chemotherapy for locally advanced stage III non-small cell lung carcinoma. Methods: Systemic doses of carboplatin AUC 6 and paclitaxel (200 mg/m2), 3 weeks out of 4, were planned as induction and consolidation chemotherapy. Weekly carboplatin AUC of 2 plus paclitaxel (50 mg/m2) were given during thoracic radiotherapy. Results: Eighteen patients were enrolled: 10 were evaluated at the end of chemoradiation and 8 received consolidation chemotherapy. On an intent-to-treat basis, 55% of patients achieved a response after induction therapy, whereas chemoradiation and consolidation therapy increased the response rate by 33% and 16%, respectively. No patient experienced grade >3 acute hematologic toxicity during systemic-dose chemotherapy. With the exception of one episode of a severe cardiac adverse event, non-hematologic toxicity was similarly tolerable. Severe acute adverse events observed during concurrent chemoradiation were mainly represented by esophagitis, resulting in interruption of the radiotherapy in 25% of patients. More notably, only one patient experienced serious non-hematologic late toxicity. Conclusions: Although the present approach seemed feasible, our data did not support any possible advantage in favor of this three-phase integrated treatment, and therefore the design will not be investigated in a subsequent phase II study.

AB - Aims and background: The purpose of this pilot study was to determine the safety and feasibility of a complete integrated approach, including induction chemotherapy with carboplatin/paclitaxel followed by accelerated hyperfractionated radiotherapy with concurrent chemotherapy, and then by consolidation chemotherapy for locally advanced stage III non-small cell lung carcinoma. Methods: Systemic doses of carboplatin AUC 6 and paclitaxel (200 mg/m2), 3 weeks out of 4, were planned as induction and consolidation chemotherapy. Weekly carboplatin AUC of 2 plus paclitaxel (50 mg/m2) were given during thoracic radiotherapy. Results: Eighteen patients were enrolled: 10 were evaluated at the end of chemoradiation and 8 received consolidation chemotherapy. On an intent-to-treat basis, 55% of patients achieved a response after induction therapy, whereas chemoradiation and consolidation therapy increased the response rate by 33% and 16%, respectively. No patient experienced grade >3 acute hematologic toxicity during systemic-dose chemotherapy. With the exception of one episode of a severe cardiac adverse event, non-hematologic toxicity was similarly tolerable. Severe acute adverse events observed during concurrent chemoradiation were mainly represented by esophagitis, resulting in interruption of the radiotherapy in 25% of patients. More notably, only one patient experienced serious non-hematologic late toxicity. Conclusions: Although the present approach seemed feasible, our data did not support any possible advantage in favor of this three-phase integrated treatment, and therefore the design will not be investigated in a subsequent phase II study.

KW - Carboplatin

KW - Concurrent chemoradiotherapy

KW - Consolidation chemotherapy

KW - Hyperfractionated radiotherapy

KW - Induction chemotherapy

KW - Non-small-cell lung cancer

KW - Paclitaxel

KW - Stage III

UR - http://www.scopus.com/inward/record.url?scp=34249877434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249877434&partnerID=8YFLogxK

M3 - Article

C2 - 17557558

AN - SCOPUS:34249877434

VL - 93

SP - 133

EP - 137

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -